These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32741945)

  • 1. Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015.
    Kawabe A; Muraki Y; Inose R; Kusama Y; Goto R; Ebisui A; Ishii S; Ishikane M; Ohge H; Ohmagari N
    Biol Pharm Bull; 2020; 43(8):1248-1252. PubMed ID: 32741945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superficial mycoses in Belgium: Burden, costs and antifungal drugs consumption.
    Becker P; Lecerf P; Claereboudt J; Devleesschauwer B; Packeu A; Hendrickx M
    Mycoses; 2020 May; 63(5):500-508. PubMed ID: 32048335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Trend for Antibiotic Use for Clostridioides (Clostridium) difficile Infection in Japan.
    Ishii S; Muraki Y; Kusama Y; Yagi T; Goto R; Ebisui A; Kawabe A; Inose R; Ohmagari N
    Biol Pharm Bull; 2020; 43(4):693-696. PubMed ID: 32238711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the current treatment of invasive fungal infection need to be reviewed?
    Martín-Peña A; Aguilar-Guisado M; Cisneros JM
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):523-8. PubMed ID: 23587702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital.
    de Souza MC; Dos Santos AG; Reis AM
    Int J Clin Pharm; 2016 Dec; 38(6):1398-1406. PubMed ID: 27714625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antifungal agents.
    Gupta AK; Tomas E
    Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of antifungal resistance and its impact on clinical practice.
    Alcazar-Fuoli L; Mellado E
    Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Antipseudomonal Agent Use Based on the 2006 to 2015 Sales Data in Japan.
    Ebisui A; Inose R; Kusama Y; Koizumi R; Kawabe A; Ishii S; Goto R; Ishikane M; Yagi T; Ohmagari N; Muraki Y
    Biol Pharm Bull; 2021; 44(6):816-821. PubMed ID: 34078813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current drug therapy of systemic mycoses: a review.
    Yonga G
    East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview about the medical use of antifungals in Portugal in the last years.
    Manuel da S Azevedo M; Cruz L; Pina-Vaz C; Gonçalves-Rodrigues A
    J Public Health Policy; 2016 May; 37(2):200-15. PubMed ID: 26865319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic antifungal drug use in Belgium-One of the biggest antifungal consumers in Europe.
    Goemaere B; Lagrou K; Spriet I; Hendrickx M; Vandael E; Becker P; Catry B
    Mycoses; 2019 Jun; 62(6):542-550. PubMed ID: 30887582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triazole antifungals: a review.
    Peyton LR; Gallagher S; Hashemzadeh M
    Drugs Today (Barc); 2015 Dec; 51(12):705-18. PubMed ID: 26798851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.
    Bauters TG; Buyle FM; Peleman R; Robays H
    Pharm World Sci; 2005 Feb; 27(1):31-4. PubMed ID: 15861932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.
    Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP
    Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.
    Parente-Rocha JA; Bailão AM; Amaral AC; Taborda CP; Paccez JD; Borges CL; Pereira M
    Mediators Inflamm; 2017; 2017():9870679. PubMed ID: 28694566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agents for treatment of invasive fungal infections.
    Luna B; Drew RH; Perfect JR
    Otolaryngol Clin North Am; 2000 Apr; 33(2):277-99. PubMed ID: 10736404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of amphotericin B in the treatment of invasive fungal infections.
    Klepser M
    J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.
    Johnson MD; Kleinberg M; Danziger L; Ostrosky-Zeichner L
    Expert Opin Pharmacother; 2005 Dec; 6(15):2617-32. PubMed ID: 16316301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.